EUnetHTA Joint Action 3 (2016 – 2020)

Home  /  Activities   /  EUnetHTA Joint Action 3 (2016 – 2020) (Page 7)

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". This is a revised version of the report originally posted on January